AVITA Medical, Inc.
NASDAQ:RCELMedical - Devices
+$0.00 today
- Market cap
- $418.11M
- Beta
- 1.86
- P/E (TTM)
- -0.0
- EPS (TTM)
- -$148.45
Volume 0.72M
Average 0.24M
RCEL Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
AVITA Medical, Inc.NASDAQ: RCEL
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue growth accelerates
Q1 FY2026 revenue of $19.25M rose 4.0% year over year, ahead of the +1.0% change in trailing-twelve-month revenue. Sequentially, it rose 9.3% from the prior quarter. Over 3 fiscal years it compounded at +27.7% a year.
Context
- Revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 5 analysts of $93.24M (+30.2%) for the fiscal year ending Dec 2026, a step up from the +11.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $19.25M+9.3% QoQ
- Last fiscal yearDec 2025
- $71.61M+11.5% YoY
- LTMMar 2026
- $72.35M+1.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +4.0% | +9.9% | +6.0 pp |
| 1 year | +11.5% | +30.2% | +18.8 pp |
| 3-year CAGR | +27.7% | +24.1% | -3.6 pp |
| 5-year CAGR | +47.4% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 71.61M USD
- Year-over-year change
- +11.5%
- 4-year CAGR
- +21.3%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 71.61M | +11.5% |
| FY2024 | 2024-12-31 | 64.25M | +28.1% |
| FY2023 | 2023-12-31 | 50.14M | +45.7% |
| FY2022 | 2022-12-31 | 34.42M | +4.2% |
| FY2021 | 2021-12-31 | 33.03M | — |
Revenue vs competitors
How RCEL compares with its peers on the latest reported figures
- RCEL's LTM Mar 2026 revenue of $72.35M is the 3rd highest of the 9 companies compared; the peer median is $11.23M.
- Its year-over-year change of +1.0% is the 6th highest of 8, against a peer median of +18.2%.
- Over three fiscal years its annual growth of +27.7% compares with a peer median of +25.8%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $121.91M | -0.3% | +32.2% | |
| LTM Mar 2026 | $105.34M | +2.3% | +2.3% | |
| LTM Mar 2026 | $72.35M | +1.0% | +27.7% | |
| LTM Mar 2026 | $55.9M | +18.2% | +5.9% | |
| LTM Mar 2026 | $15.33M | +30.7% | +25.8% | |
| LTM Mar 2026 | $7.12M | +1199.6% | +69.0% | |
| LTM Mar 2026 | $5.13M | +23.0% | +132.0% | |
| LTM Mar 2026 | $1M | -78.3% | +15.3% | |
| LTM Mar 2026 | $0 | — | — | |
| Peer median (excluding RCEL) | $11.23M | +18.2% | +25.8% | |
Competitors are the stored peer set for RCEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 33.03M | 34.42M | 50.14M | 64.25M | 71.61M |
| Cost of Revenue | 6.1M | 6.04M | 7.78M | 9.09M | 12.79M |
| Gross Profit | 26.92M | 28.38M | 42.36M | 55.16M | 58.82M |
| Gross Margin | 81.5% | 82.4% | 84.5% | 85.8% | 82.1% |
| Research & Development | 15.67M | 13.86M | 20.82M | 20.36M | 20.84M |
| Selling, General & Admin | 37.21M | 45.24M | 65.63M | 91.39M | 79.91M |
| Operating Expenses | 52.04M | 55.89M | 85.02M | 111.75M | 100.75M |
| Depreciation & Amortization | 673K | 568K | 632K | 1.13M | 2.35M |
| EBITDA | (24.4M) | (26.05M) | (33.54M) | (55.3M) | (39.59M) |
| EBITDA Margin | -73.9% | -75.7% | -66.9% | -86.1% | -55.3% |
| Operating Income | (25.12M) | (27.51M) | (42.66M) | (56.59M) | (41.93M) |
| Operating Margin | -76.1% | -79.9% | -85.1% | -88.1% | -58.6% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 29K | 16K | 1.14M | 5.36M | 5M |
| Other Income / Expenses | 18K | 876K | 7.34M | (5.2M) | (6.64M) |
| Income Before Tax | (25.1M) | (26.63M) | (35.32M) | (61.79M) | (48.58M) |
| Pre-Tax Margin | -76.0% | -77.4% | -70.4% | -96.2% | -67.8% |
| Income Tax Expense | 42K | 36K | 66K | 54K | 11K |
| Net Income | (25.14M) | (26.67M) | (35.38M) | (61.85M) | (48.59M) |
| Net Margin | -76.1% | -77.5% | -70.6% | -96.3% | -67.8% |
| EPS (Basic) | (1.03) | (1.07) | (1.40) | (2.39) | (1.74) |
| EPS (Diluted) | (1.03) | (1.07) | (1.40) | (2.39) | (1.74) |
| Weighted Avg Shares | 24.36M | 25M | 25.33M | 25.88M | 27.86M |
| Weighted Avg Shares (Diluted) | 24.36M | 25M | 25.33M | 25.88M | 27.86M |
AVITA Medical, Inc.
NASDAQ:RCEL
Intrinsic Alpha fair value
Locked
Current Price
$16.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.